Advances in Molecular Profiling and GLP-1 Therapy Offer Hope in Endometrial Cancer

In this interview with Pharmacy Times, Jennifer MacDonald, PharmD, BCOP, MUSC Oncology PGY2 Residency Program Director, Clinical Oncology Pharmacy Specialist at Hollings Cancer Center, discusses the evolving role of molecular profiling and GLP-1 receptor agonists in the management of endometrial cancer. MacDonald explains how biomarker-driven treatment selection is reshaping uterine cancer care, particularly as clinicians move beyond traditional staging to incorporate molecular classifications such as POLE mutations, mismatch repair status, p53 alterations, and HER2 expression into therapeutic decision-making. She highlights the growing role pharmacists play in interpreting complex molecular assay results and helping guide personalized treatment strategies.